Bausch+Lomb Results Presentation Deck
Total Bausch+Lomb P&L¹ (Non-GAAP)² - YTD
Bausch + Lomb
Vision Care Revenue
Surgical Revenue
Ophthalmic Pharmaceuticals Revenue
Total Revenue
Adj. Gross Profit²
Adj. Gross Margin ²
R&D
R&D percent of Revenues.
Adj. SG&A²
Adj. SG&A percent of Revenues²
Adj. EBITA 2,6
Depreciation
Stock Based Compensation
Adj. EBITDA 2,3,6
Adj. EBITDA Margin 2,6
Adj. Net Income ³,6
Adj EPS 2,4,6
3Q22-1022
$1,747M
$530M
$495M
$2,772M
$1,673M
60.4%
$229M
8.3%
$1,060M
38.2%
$383M
$98M
$45M
$539M
19.4%
$295M
$0.84
3Q21-1Q21
$1,717M
$520M
$527M
$2,764M
$1,700M
61.5%
$201M
7.3%
$1,016M
36.8%
$483M
$90M
$45M
$605M
21.9%
$333M
$0.95
1. Products with sales outside the United States impacted by F/X changes.
2. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios.
3. Includes transactional FX and NCI.
Reported Change
2%
2%
(6%)
0%
(2%)
(110 bps)
(14%)
(4%)
(21%)
9%
0%
(11%)
(11%)
Constant Currency³
7%
8%
(3%)
5%
2%
(17%)
(9%)
(18%)
14%
0%
(14%)
(16%)
4. On a proforma basis after giving effect to the IPO.
BAUSCH + LOMB 5. Organic revenue growth/change, a non-GAAP ratio, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.
Organic Change ³,5
7%
9%
(3%)
5%
6. Prior to 2022, in calculating this non-GAAP measure/ratio, the Company had excluded expenses associated with acquired IPR&D. Commencing in 2022, the Company no longer excludes acquired IPR&D in calculating these amounts. The Company believes these
costs are not material for the periods presented. See the Appendix for further information on this change.
32View entire presentation